Report overview
Cardiovascular Drugs and Therapy is a bimonthly peer-reviewed medical journal covering pharmacotherapy as it relates to cardiology. It was established in 1987 and is published by Springer Science+Business Media on behalf of the International Society of Cardiovascular Pharmacotherapy, of which it is the official journal. The editors-in-chief are Willem J. Remme (Carol Davila University of Medicine and Pharmacy) and Robert S. Rosenson (Icahn School of Medicine at Mount Sinai).
This report aims to provide a comprehensive presentation of the global market for Cardiovascular Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cardiovascular Drugs. This report contains market size and forecasts of Cardiovascular Drugs in global, including the following market information:
Global Cardiovascular Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Cardiovascular Drugs Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Cardiovascular Drugs companies in 2022 (%)
The global Cardiovascular Drugs market was valued at US$ 6189 million in 2022 and is projected to reach US$ 6525.7 million by 2029, at a CAGR of 0.8% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Geographically, North America captured lion?s share of global cardiovascular drugs market in 2016. However increasing adoption of generics in the U.S. is key concern area among key players. Asia Pacific market is projected to gain market share during the forecast period and is likely to be key revenue generator in the coming years. Initiatives by local governments to attain self-sufficiency in manufacturing pharmaceuticals and incentives for generic production in countries such as Brazil, South Africa, Saudi Arabia, etc. is likely to boost market growth in Latin America and Middle East & Africa.
We surveyed the Cardiovascular Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Cardiovascular Drugs Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Cardiovascular Drugs Market Segment Percentages, by Type, 2022 (%)
Renin-Angiotensin System Blockers
Beta Blockers
Diuretics
Anti-Clotting Agents
Antihyperlipidemic
Global Cardiovascular Drugs Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Cardiovascular Drugs Market Segment Percentages, by Application, 2022 (%)
Hypertension
Hyperlipidemia
Global Cardiovascular Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Cardiovascular Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Cardiovascular Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Cardiovascular Drugs revenues share in global market, 2022 (%)
Key companies Cardiovascular Drugs sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Cardiovascular Drugs sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Amgen
AstraZeneca
Bayer
Bristol Myers Squibb and Pfizer
Daiichi Sankyo
Johnson & Johnson
Merck & Co.
Novartis
Pfizer
Portola
Sanofi
Outline of Major Chapters:
Chapter 1: Introduces the definition of Cardiovascular Drugs, market overview.
Chapter 2: Global Cardiovascular Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Cardiovascular Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Cardiovascular Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Cardiovascular Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
